このページの翻訳は実験的なもので、現在開発中です。お待ちしております!
Bio-Rad Laboratories 将来の成長
Future 基準チェック /36
Bio-Rad Laboratories利益と収益がそれぞれ年間32.8%と3.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に3.3% 32.6%なると予測されています。
主要情報
32.8%
収益成長率
32.6%
EPS成長率
Life Sciences 収益成長 | 16.2% |
収益成長率 | 3.8% |
将来の株主資本利益率 | 3.3% |
アナリストカバレッジ | Low |
最終更新日 | 22 Jun 2024 |
今後の成長に関する最新情報
Recent updates
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?
Feb 07Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?
Dec 17Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Nov 20Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?
Oct 02We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Aug 21Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?
Jul 30Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 04Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?
May 23A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
May 01Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Apr 04Bio-Rad Labs reports Q4 2022 results
Feb 16Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?
Feb 10Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jan 20Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching
Dec 08Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M
Oct 27A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Oct 14Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal
Oct 12Bio-Rad Laboratories hits 52-week low; down 40% YTD
Sep 19Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Sep 02Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M
Jul 28When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Jul 25Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jul 04Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet
May 02Bio-Rad Offers Value If You Look
Mar 28Bio-Rad Laboratories: Relentless Growth Supports A Bullish Outlook
Dec 25Is Now The Time To Look At Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Dec 10業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 2,893 | 326 | N/A | N/A | 4 |
12/31/2025 | 2,796 | 285 | N/A | N/A | 5 |
12/31/2024 | 2,663 | 294 | N/A | N/A | 5 |
3/31/2024 | 2,605 | -322 | 185 | 347 | N/A |
12/31/2023 | 2,671 | -637 | 218 | 375 | N/A |
9/30/2023 | 2,720 | -159 | 223 | 374 | N/A |
6/30/2023 | 2,769 | -428 | 153 | 287 | N/A |
3/31/2023 | 2,779 | -191 | 125 | 242 | N/A |
12/31/2022 | 2,802 | -3,628 | 80 | 194 | N/A |
9/30/2022 | 2,805 | -6,021 | 152 | 286 | N/A |
6/30/2022 | 2,871 | -1,930 | 364 | 505 | N/A |
3/31/2022 | 2,896 | -91 | 459 | 606 | N/A |
12/31/2021 | 2,923 | 4,254 | 536 | 670 | N/A |
9/30/2021 | 2,980 | 6,659 | 670 | 783 | N/A |
6/30/2021 | 2,880 | 4,045 | 590 | 689 | N/A |
3/31/2021 | 2,701 | 4,098 | 533 | 626 | N/A |
12/31/2020 | 2,546 | 3,814 | 480 | 585 | N/A |
9/30/2020 | 2,380 | 3,521 | 378 | 450 | N/A |
6/30/2020 | 2,294 | 1,947 | 323 | 414 | N/A |
3/31/2020 | 2,329 | 1,579 | 383 | 478 | N/A |
12/31/2019 | 2,312 | 1,759 | 368 | 458 | N/A |
9/30/2019 | 2,304 | 377 | 272 | 403 | N/A |
6/30/2019 | 2,289 | 905 | 251 | 366 | N/A |
3/31/2019 | 2,292 | 574 | 169 | 288 | N/A |
12/31/2018 | 2,289 | 366 | 156 | 285 | N/A |
9/30/2018 | 2,294 | 1,277 | 148 | 250 | N/A |
6/30/2018 | 2,283 | 1,030 | 116 | 216 | N/A |
3/31/2018 | 2,212 | 767 | 98 | 201 | N/A |
12/31/2017 | 2,160 | 122 | N/A | 104 | N/A |
9/30/2017 | 2,110 | 17 | N/A | 130 | N/A |
6/30/2017 | 2,085 | 13 | N/A | 153 | N/A |
3/31/2017 | 2,097 | 26 | N/A | 168 | N/A |
12/31/2016 | 2,068 | 26 | N/A | 216 | N/A |
9/30/2016 | 2,067 | 98 | N/A | 157 | N/A |
6/30/2016 | 2,028 | 97 | N/A | 188 | N/A |
3/31/2016 | 2,018 | 108 | N/A | 149 | N/A |
12/31/2015 | 2,019 | 109 | N/A | 186 | N/A |
9/30/2015 | 2,047 | 103 | N/A | 190 | N/A |
6/30/2015 | 2,108 | 97 | N/A | 199 | N/A |
3/31/2015 | 2,139 | 100 | N/A | 237 | N/A |
12/31/2014 | 2,175 | 89 | N/A | 273 | N/A |
9/30/2014 | 2,179 | 80 | N/A | 304 | N/A |
6/30/2014 | 2,154 | 61 | N/A | 268 | N/A |
3/31/2014 | 2,142 | 64 | N/A | 211 | N/A |
12/31/2013 | 2,133 | 78 | N/A | 169 | N/A |
9/30/2013 | 2,104 | 91 | N/A | 194 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: BIOは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。
収益対市場: BIO今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。
高成長収益: BIO今後 3 年以内に収益を上げることが予想されます。
収益対市場: BIOの収益 ( 3.8% ) US市場 ( 8.7% ) よりも低い成長が予測されています。
高い収益成長: BIOの収益 ( 3.8% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: BIOの 自己資本利益率 は、3年後には低くなると予測されています ( 3.3 %)。